BioPlus Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses in the life sciences industry. The company was incorporated in 2021 and is based in New York, New York.
IPO Year: 2022
Exchange: NASDAQ
Website: https://bioplusspac.com
SC 13G/A - BioPlus Acquisition Corp. (0001856653) (Subject)
SC 13G/A - BioPlus Acquisition Corp. (0001856653) (Subject)
SC 13G/A - BioPlus Acquisition Corp. (0001856653) (Subject)
SC 13G/A - BioPlus Acquisition Corp. (0001856653) (Subject)
SC 13D/A - BioPlus Acquisition Corp. (0001856653) (Subject)
SC 13G/A - BioPlus Acquisition Corp. (0001856653) (Subject)
SC 13G/A - BioPlus Acquisition Corp. (0001856653) (Subject)
SC 13G - BioPlus Acquisition Corp. (0001856653) (Subject)
SC 13G - BioPlus Acquisition Corp. (0001856653) (Subject)
SC 13G - BioPlus Acquisition Corp. (0001856653) (Subject)
4 - BioPlus Acquisition Corp. (0001856653) (Issuer)
Company to Welcome New Directors to Board Adam Gray to Serve as Board Chair Gary DiCamillo to Continue to Serve as Lead Independent Director Company Will Redeem Cumulative Voting Proportional Representation Preferred Linked Stock Purple Innovation, Inc. (NASDAQ:PRPL) ("Purple" or the "Company"), a comfort innovation company known for creating the "World's First No Pressure® Mattress," today announced that it has entered into a binding Memorandum of Understanding to establish a cooperative governance framework (the "Planned Cooperation Agreement") with Coliseum Capital Management, LLC (together with its managed funds and accounts, "Coliseum"), the largest stockholder of the Company o
15-12G - BioPlus Acquisition Corp. (0001856653) (Filer)
25-NSE - BioPlus Acquisition Corp. (0001856653) (Subject)
RW - BioPlus Acquisition Corp. (0001856653) (Filer)
8-K - BioPlus Acquisition Corp. (0001856653) (Filer)
425 - BioPlus Acquisition Corp. (0001856653) (Subject)
425 - BioPlus Acquisition Corp. (0001856653) (Subject)
10-Q - BioPlus Acquisition Corp. (0001856653) (Filer)
S-4/A - BioPlus Acquisition Corp. (0001856653) (Filer)
425 - BioPlus Acquisition Corp. (0001856653) (Subject)
S-4/A - BioPlus Acquisition Corp. (0001856653) (Filer)
New York, NY, Oct. 04, 2023 (GLOBE NEWSWIRE) -- BioPlus Acquisition Corp. ("BIOS" or the "Company") (NASDAQ:BIOS) announced today that (i) BIOS, Avertix Medical, Inc. and certain other parties have mutually agreed to terminate their previously announced business combination agreement and plan of reorganization (the "Business Combination Agreement"), effective as of October 4, 2023 and (ii) it intends to liquidate as soon as practicable after October 4, 2023 and to return funds to holders of its Class A ordinary shares that were included in the units issued in the Company's initial public offering ("Public Shares"). The Business Combination Agreement was dated as of May 2, 2023. The pa
EATONTOWN, N.J. and NEW YORK, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Avertix Medical, Inc. ("Avertix" or the "Company"), formerly known as Angel Medical Systems, Inc., a company focused on improving long-term management and outcomes of high-risk coronary disease in patients who have survived one or more heart attacks, and BIOS Acquisition Corporation (dba BioPlus Acquisition Corp.) ("BIOS") (NASDAQ:BIOS), a special purpose acquisition company, announced today that the two companies have mutually agreed to terminate their proposed business combination. "While we were enthusiastic about the potential business combination with BIOS, we mutually agreed that the current market conditions are not co
Bioservo signs a Sales Agent agreement with Trivet Medical LLC for sales of Carbonhand to Hospitals, Clinics, and Medical Centers within the Veterans Health Administration and Department of Defense in the US. With the first Sales Agent in place, the grip-strengthening device Carbonhand is available for all US Veterans suffering from impaired hand function. KISTA, Sweden, Aug. 29, 2023 /PRNewswire/ -- Trivet Medical LLC is a specialized strategic sales and distribution LLC, highly focused on commercializing disruptive, best-in-class med-tech devices and technologies. Founded by Charles Coyle, Trivet Medical's mission is to develop underrepresented and underserved healthcare conditions through
The Avertix Guardian™ System, the first and only FDA approved implantable heart attack warning system, now available at the Heart & Rhythm Institute of Trinity, extending their commitment to redefining cardiac care in the Tampa, FL area Dr. Luis R. Annoni-Suau, MD, FACC and Dr. Carlos J. Bayron successfully performed the first two Guardian implants at the Heart and Rhythm Institute of Trinity EATONTOWN, N.J. and TRINITY, Fla., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Avertix Medical, Inc. ("Avertix" or the "Company"), a company focused on improving long-term management and outcomes of high-risk coronary disease in patients who have survived one or more heart attacks, and the Heart & Rhythm Inst
Bioservo signs a wholesale distributor agreement with Veterans Healthcare Supply Solutions for sales of Carbonhand in the US. The initial intent of the agreement is to make Carbonhand available for Veterans Administration Facilities (VA) and Department of Defense Healthcare Facilities (DoD). The agreement can also be expanded to include other customer segments. STOCKHOLM, Aug. 16, 2023 /PRNewswire/ -- Veterans Healthcare Supply Solutions (VHSS) has over 30 years of healthcare distribution management experience and represents leading manufacturers to federal government agencies. Established in 2010, VHSS has been a veteran-driven medical product distribution company and has taken the collect
Recently served as Boston Scientific Executive Vice President and Global Chief Medical Officer Professor Meredith brings to Avertix over 35 years of cardiology experience and commitment to advancing cardiac care EATONTOWN, N.J., July 17, 2023 (GLOBE NEWSWIRE) -- Avertix Medical, Inc. ("Avertix" or the "Company"), formerly known as Angel Medical Systems, Inc., a healthcare technology company commercializing the first and only FDA-approved heart attack warning system to improve long-term management and outcomes of high-risk coronary disease in patients, announced today that Professor Ian Meredith AM, has agreed to join the Company's Board of Directors following the closing of the Company's
EATONTOWN, N.J. and ORLANDO, Fla., June 13, 2023 (GLOBE NEWSWIRE) -- Avertix Medical, Inc. ("Avertix" or the "Company"), formerly known as Angel Medical Systems, Inc., a company focused on improving long-term management and outcomes of high-risk coronary disease in patients who have survived one or more heart attacks, and AdventHealth Orlando, a nationally-ranked hospital system in Florida, today announced the availability of the Guardian™ System, the first and only FDA-approved implantable heart attack detection and warning system, at AdventHealth Orlando. The Guardian System, developed by Avertix, is designed to detect acute coronary syndrome events, such as heart attacks, in real-time,
- Transaction values Avertix at an enterprise value of $195 million- Avertix developed the Guardian™ System, the first and only FDA-approved solution designed to detect and warn patients of cardiac events, including silent heart attacks EATONTOWN, N.J. and NEW YORK, May 03, 2023 (GLOBE NEWSWIRE) -- Avertix Medical, Inc. ("Avertix" or the "Company"), formerly known as Angel Medical Systems, Inc., a company focused on improving long-term management and outcomes of high-risk coronary disease in patients who have survived one or more heart attacks, and BIOS Acquisition Corporation (dba BioPlus Acquisition Corp.) ("BIOS") (NASDAQ:BIOS), a special purpose acquisition company, today announced
Company to Welcome New Directors to Board Adam Gray to Serve as Board Chair Gary DiCamillo to Continue to Serve as Lead Independent Director Company Will Redeem Cumulative Voting Proportional Representation Preferred Linked Stock Purple Innovation, Inc. (NASDAQ:PRPL) ("Purple" or the "Company"), a comfort innovation company known for creating the "World's First No Pressure® Mattress," today announced that it has entered into a binding Memorandum of Understanding to establish a cooperative governance framework (the "Planned Cooperation Agreement") with Coliseum Capital Management, LLC (together with its managed funds and accounts, "Coliseum"), the largest stockholder of the Company o
Will Support Re-Election of CEO Rob DeMartini to Board No Longer Pursuing September 2022 Take Private Proposal Shareholders Deserve Nimbler, More Engaged Board with Heightened Sense of Urgency and Bias for Action to Help Management Navigate Challenges Ahead Coliseum Capital Partners, L.P. ("Coliseum"), the largest stockholder of Purple Innovation, Inc. (NASDAQ:PRPL) ("Purple"), announced today that it has nominated five candidates for election to Purple's seven member Board of Directors at the company's 2023 Annual Meeting of Stockholders, including Adam Gray, a current Purple director and Managing Partner and Co-Founder of Coliseum Capital Management, LLC. Coliseum also announced that